October 14, 2019
Mogrify raises additional $16M, (total $20M) in series A funding
Mogrify has raised additional $16 million to advance its mission to transform the development of life-saving cell therapies, with initial…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
October 14, 2019
Abzena Names Kimball Hall as Chief Operating Officer
SAN DIEGO, Calif.–(BUSINESS WIRE)–Abzena announced today the appointment of Kimball Hall as Chief Operating Officer, adding to the company’s executive…
October 14, 2019
Novigenix and RadioMedix set to work on neuroendocrine cancer precision diagnostic test
Novigenix and RadioMEdix have announced collaboration on developing a test to measure response to radiopharmaceutical therapy, based on Novigenix’s technology.
October 13, 2019
Pfizer’s abrocitinib met all endpoints in moderate to severe atopic dermatitis study
Pfizer has presented positive phase 3 data at the 28th Congress of the European Academy of Dermatology and Venereology for abrocitinib in moderate to severe atopic dermatitis, in which abrocitinib met all co-primary and secondary endpoints in JADE MONO-1 study.
October 11, 2019
Kangpu Biopharmaceuticals doses first humans with KPG-818 for treating SLE and hematological malignancies
Kangpu Biopharmaceuticals has completed a first-in-human phase I single ascending dose (SAD) clinical study in the United States, testing KPG-818 for the treatment of SLE and hematological malignancies.
October 10, 2019
Boehringer Ingelheim nets breakthrough therapy designation for Ofev, for chronic fibrosing interstitial lung diseases
FDA has granted to Boehringer Ingelheim a breakthrough therapy designation for Ofev, for Chronic Fibrosing ILDs with a Progressive Phenotype, after the study results from the Phase III testing met its primary endpoint and was recently published in the New England Journal of Medicine.
October 10, 2019
Aerpio Pharmaceuticals encouraged phase 1b trial of topical ocular formulation for primary open angle glaucoma
Aerpio Pharmaceutical encouraged by the early safety findings and potential efficacy signal of this ongoing Phase 1b trial.
October 10, 2019
City of Hope Helps Found Biotechnology Hub for Los Angeles County’s Life Sciences Industry
Harlan Levine, M.D., president of strategy and business ventures at City of Hope, joins the governing board of the bioscience…
October 10, 2019
MGB Biopharma sees promising results from phase IIa clinical trial for potent oral bactericidal antibiotic targeting CDAD
MGB Biopharma has announced promising phase IIa clinical trial update for oral formulation MGB-BP-3, a potent oral bactericidal antibiotic targeting Clostridium Difficile-Associated Diarrhoea (CDAD), with – as it said in a press release – a completely novel mode of action.
October 10, 2019
Heidelberg Pharma doubles revenue, net loss falls to €5.6, in first nine months
Heidelberg Pharma reported that its net loss for the first nine months of the fiscal year fell to €5.6 million from previous year’s €7.4 million, referring the result to the sales revenue and income totaling €6.7 million, from €3.5 million in the same period last year.